Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

The study, “… A European Medicines Agency (EMA) committee has recommended the approval of Novo Nordisk’s concizumab as a prophylactic, or preventive, treatment for adults and children, ages 12 and ...

Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other chronic ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...